- Home
- CNTX vs ALDX Comparison
CNTX vs ALDX Comparison
Compare CNTX & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTX | ALDX |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.7M | 39.2M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CNTX | ALDX |
|---|---|---|
| Price | $0.24 | $0.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | $4.14 | ★ $6.60 |
| AVG Volume (30 Days) | 971.2K | ★ 1.8M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.39 | ★ 40.43 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.60 |
| 52 Week High | $3.62 | $5.93 |
Technical Indicators
Market Signals| Indicator | CNTX | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 29.57 | 26.66 |
| Support Level | N/A | N/A |
| Resistance Level | $0.36 | $1.58 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 23.87 | 9.82 |
Price Performance
Historical ComparisonAbout CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.